Tianyin Pharmaceuticals (TPI) Q4 2011 Results September 27, 2011 9:00 a.m. ET Executives James Jiayuan Tong – Chief Financial Officer and Chief Business & Development Officer Analysts Adam Waldo – Lismore Partners LLC PresentationOperator
Good day ladies and gentlemen and thank you for standing by. Welcome to the Tianyin Pharmaceutical fiscal year 2011 annual financial results conference call. [Operator instructions.] I would now like to turn the conference over to James Tong of Tianyin Pharmaceuticals. Please go ahead. James Jiayuan Tong Thank you operator. Good morning, good evening ladies and gentlemen. Welcome to Tianyin Pharmaceutical fiscal year 2011 earnings conference call. I am James Jiayuan Tong, chief financial officer and chief business development officer of TPI along with Dr. Jiang Guoqing, chairman and chief executive officer of the company, and Simon Minute Ren, director of investor relations of Tianyin Pharmaceutical. During this conference call we will be reviewing the fiscal year 2011 financial highlights followed by the question and answer period. Before we continue please know that this call will contain forward-looking statements made under the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995. Any statements set forth in this presentation that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, fluctuation in the economy, results of research and development, failure to obtain regulatory approvals and other information detailed from time to time in TPI’s filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this presentation are made only for this date and TPI is not under any obligation to revise or update these forward-looking statements.